Collectively, these findings suggest that central leptin resistance in AD probably arises from disrupted receptor expression, sequestration by pathological aggregates, and inhibition of downstream pathways by SOCS3 and PTP1B, thereby weakening leptin’s neuroprotective potential. This evidence concerns the gene PTPN1 and Alzheimer disease.